Abstract:

Chronic kidney disease-mineral and bone disorder (CKD-MBD) is the most common complication of chronic kidney disease. It is due to the decline in glomerular filtration rate, which leads to the retention of multiple substances and toxins. Its clinical manifestations includes disorders of blood calcium, phosphorus and related regulatory hormones such as parathyroid hormone, vitamin D, and fibroblast growth factor 23, which in turn cause metabolic bone disease or fractures, and cardiovascular diseases, and increase the hospitalization rate and mortality of patients. The "China guidelines for the diagnosis and treatment of CKD-MBD" launched in 2018 has played a very good role in standardizing the diagnosis and treatment of CKD-MBD. This article interpreted the CKD-MBD guidelines combing with the clinical experience of the authors.

Key words: Chronic kidney disease-mineral and bone disorder (CKD-MBD), Secondary hyperparathyroidism (SHPT)